Earli, Inc


Earli is developing a new orthogonal approach for early cancer detection and localization, making the disease actionable a stage when the chances of survival are significantly higher. Rather than rely on naturally shed biomarkers that cancer may or may not provide, Earli’s platform technology usurps the dysregulated pathways that cause malignancy and *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It’s called a Synthetic Biopsy. It can then localize the cancer in a PET scanner, and even be extended to therapeutics.

Company Information

January 31, 2022